Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 19 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2014 New trial record